Medzar

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Medzar

Property Description
Active ingredient Losartan Potassium
Form Oral tablet (Film-coated)
Pharmacological class Angiotensin II Receptor Blocker (ARB)
General purpose To lower high pressure in the circulatory system
Origin Synthetic, Non-peptide molecule

What is Medzar and What Pharmacological Class Does it Belong To?

Medzar is a prescription-only medicine that contains the active substance Losartan Potassium, a synthetic compound utilized in the management of high circulatory pressure. It is definitively classified as an Angiotensin II Receptor Blocker (ARB), a class of drugs utilized for treating certain cardiovascular conditions. This means that the medicine works to control tension in the blood vessels, which can become too high, a mechanism utilized for its sustained efficacy in adults.

Losartan is a single-ingredient product, often identified commercially by other names like Cozaar, developed for oral delivery. As a non-peptide molecule, its chemical structure facilitates effective absorption via the oral route of administration. The pharmacological ARB category acts by directly and selectively blocking a specific receptor site, providing a distinct mode of interference within the complex Renin-Angiotensin-Aldosterone System (RAAS).

Composition and Form: What Kind of Preparation is Medzar?

Medzar is predominantly supplied as an oral tablet, commonly manufactured with a film-coating designed to aid ingestion and ensure consistent release of the active agent. The foundational component is Losartan Potassium, a monopotassium salt formulation of the Losartan compound, which possesses the molecular formula C22H22ClKN6O. The chemical profile confirms the precise structure of the active substance within the medicine.

While the solid tablet is the primary form for adults, Losartan can also be specially prepared as an oral suspension to accommodate specific patient needs, such as individuals, including pediatric groups older than six years of age, who may struggle with swallowing solid tablets.

General Purpose of Angiotensin II Receptor Blockers (ARBs)

The general purpose of ARBs, including Medzar, is to relieve tension in the blood vessels by preventing the constricting effects of the potent hormone Angiotensin II. By reliably interfering with this hormonal system, the medication promotes vasodilation, which is the widening of the arteries.

This systemic relaxation of the blood vessels lowers the overall peripheral resistance, thereby reducing the workload on the heart. Ultimately, this foundational action helps to effectively manage and stabilize high pressure within the circulatory system over time, making it a critical tool for maintaining vascular health.

What side effects are possible with Medzar?

Officially Documented Adverse Reactions and Safety Profile

The safety profile of Medzar (Losartan Potassium) is defined by regulatory bodies through specific frequency classifications and System-Organ Class (SOC) groupings. These classifications differentiate between expected effects and those considered rare or serious, based on clinical trial and post-marketing data.

Common Adverse Reactions (those seen in 1 to 10 out of every 100 patients) often include dizziness, fatigue, upper respiratory infection, and nasal congestion. Laboratory abnormalities such as hyperkalaemia and anemia are also documented as common occurrences in specific patient groups.

Uncommon Adverse Reactions (seen in less than 1 in 100 patients) span several systems and may include headache, somnolence, palpitations, nausea, vomiting, or rash.

Rare and Serious Adverse Reactions

The most serious documented safety concerns, although rare, are explicitly highlighted in the official labeling. These include Angioedema (swelling of the face, lips, throat, and/or tongue) and serious hypersensitivity reactions. The medicine is contraindicated due to the risk of Fetal Toxicity if used during the second and third trimesters of pregnancy.

Population-Specific and Contextual Safety Constraints

Safety statements in regulatory documents impose specific constraints on use. Medzar is contraindicated in patients with severe hepatic impairment. Furthermore, the co-administration of Medzar with aliskiren-containing products is specifically contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment. Symptomatic hypotension is noted as a risk, particularly in patients who are volume- or salt-depleted, and may occur after the first dose or after increasing the dose.

Overdose and Emergency Response

The official regulatory profile for Medzar (Losartan Potassium) overdose is defined by the expected extension of its effects on the circulatory system. The most likely clinical manifestation of an overdosage is hypotension, or abnormally low blood pressure. Other documented presentations include a rapid heart rate (tachycardia), and potentially a slow heart rate (bradycardia), which is noted as potentially resulting from parasympathetic (vagal) stimulation.

When Immediate Medical Help Is Required

Urgent medical attention is required whenever symptomatic hypotension occurs. The regulatory documentation explicitly mandates that symptomatic and supportive treatment must be instituted immediately in such severe overdose scenarios. The patient may need to be placed in a supine position to help manage the low blood pressure.

The official overdose profile establishes that no specific antidote is available for Losartan Potassium overdosage. Furthermore, a key procedural constraint noted in the labeling is that neither Losartan nor its active metabolite can be removed to any significant extent by hemodialysis. The overall profile requires prompt professional medical intervention whenever severe cardiovascular manifestations occur, guiding the required emergency medical response as directed by regulatory authorities.

Therapeutic Uses of Medzar

Medzar is commonly used to help manage symptoms related to physical discomfort and conditions marked by episodic or fluctuating symptom patterns. Its role is generally supportive symptomatic relief, particularly in situations where symptoms create noticeable physiological strain and interfere with daily functioning. Addressing symptoms related to physical discomfort and inflammatory states is an important therapeutic focus.

Medzar is generally applied to address symptom clusters associated with pain and aches, inflammatory states, and symptoms that interfere with daily functioning. It is relevant in clinical settings that involve acute or unstable symptom patterns, such as during phases of increased physical tension or temporary symptomatic escalation. Medzar may be part of symptomatic management that assists patients with maintaining functional stability and coping more steadily with difficult episodes.


Quick Fact: Relief for Discomfort and Stiffness

Medzar supports patients during symptomatic periods by easing the impact of pain and helping to manage the symptom clusters related to inflammatory or irritative states. This application contributes to easing the overall symptom load.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

This section summarizes the official eligibility and non-eligibility requirements for Medzar based on authoritative governmental regulatory documents. Only the populations defined in the mandatory Contraindications, Restrictions, and Use in Specific Populations sections of the label are listed.

Populations That Must Not Use Medzar (Contraindications)

Medzar is strictly contraindicated and must not be used by the following patient groups:

  • Pregnancy (Second and Third Trimesters): Use is prohibited due to the established risk of severe fetal injury and death. Discontinuation is advised as soon as pregnancy is detected.
  • Hypersensitivity: Patients with a known hypersensitivity (e.g., a history of angioedema) to Medzar or any of its components.
  • Co-administration with Aliskiren: Patients diagnosed with diabetes mellitus must not take Medzar concurrently with any medicine containing aliskiren.
  • Anuria: In patients who are unable to produce urine.

Eligibility Restrictions and Special Considerations

Patient Group Regulatory Status
Pediatric Use Use in children is generally not established or is restricted, and it is not recommended for young children (e.g., under 6 years of age or with specific GFR limits in some contexts).
Renal Impairment Avoid co-administration with aliskiren in non-diabetic patients with moderate to severe renal impairment (e.g., GFR <60 mL/min/1.73 m^2).
Lactation Not recommended during breastfeeding due to the potential for adverse effects on the nursing infant.

These official regulatory statements define the strict constraints on who may use the medicine.

What should I know about interactions with other medicines?

Medzar Interactions with other medicines and products

Medzar (Losartan Potassium) interaction patterns are formally defined in regulatory documents based on pharmacokinetic and pharmacodynamic outcomes, leading to specific restrictions on coadministration.


Official Interaction Restrictions

Coadministration with Aliskiren is strictly contraindicated in patients diagnosed with diabetes mellitus or those with moderate to severe renal impairment (Glomerular Filtration Rate < 60 mL/min/1.73 m^2). The dual blockade of the Renin-Angiotensin System is generally not recommended.


Pharmacodynamic and Exposure Effects

  • Potassium-Affecting Agents: Concomitant use with potassium-sparing diuretics (e.g., Spironolactone, Triamterene) or potassium supplements/salt substitutes is officially not recommended due to the significant risk of hyperkalemia (increased serum potassium levels).
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Coadministration may officially reduce the antihypertensive effect of Losartan and increases the potential for worsening renal function.
  • Lithium: Losartan reduces the renal clearance of Lithium, which may lead to officially increased serum Lithium concentrations and potential toxicity.
  • CYP Enzyme Inhibitors/Inducers: The pharmacokinetic profile is affected by agents that alter metabolism. Fluconazole officially increases the exposure of the active metabolite (E-3174), while inducers like Rifampin officially reduce the exposure of both Losartan and its active metabolite.
  • Food: Regulatory documents state that Losartan may be taken with or without food, as food does not cause a clinically significant change in its plasma concentration profile.

Mechanism of Action

How Medzar Works: Mechanism of Action

Medzar functions as a selective, competitive antagonist (blocker) of the Angiotensin II Type 1 ( AT1) receptor. This receptor is integral to the Renin-Angiotensin-Aldosterone System ( RAAS) and is located on vascular smooth muscle, the adrenal glands, and the kidneys. By competitively binding to AT1, Medzar prevents the vasoconstrictor hormone, Angiotensin II ( Ang II), from initiating its signaling effects.

This blockade interrupts the Ang II-mediated molecular cascade in the vasculature, resulting in vasodilation and a subsequent reduction in systemic vascular resistance. Simultaneously, the decreased Ang II activity reduces the release of aldosterone from the adrenal glands. In the kidneys, this promotes the excretion of sodium and water (natriuresis/diuresis), contributing to the modulation of circulating fluid volume. The mechanism also restricts Ang II's trophic signaling, influencing cellular proliferation pathways in cardiac and vascular tissues.

Dosage and Administration Information

How to Use Medzar: Official Administration Guidelines

Losartan Potassium (Medzar) is administered exclusively via the oral route, utilizing either a film-coated tablet or a specially prepared oral suspension.


Administration Details and Dosage Structure

Feature Guideline
Standard Dosing Frequency The medicine is taken once daily (qDay).
Adult Starting Dose The usual adult starting dose is 50 mg once daily.
Maximum Daily Dose The maximum recommended daily dose for adults is 100 mg once daily.
Intake Condition Tablets may be administered with or without food.
Tablet Use Tablets should be swallowed whole with water.

Population and Procedural Adjustments

Specific conditions may involve a modified starting dose. A lower starting dose of 25 mg once daily is specified for adults who are volume-depleted or who have mild-to-moderate hepatic impairment. For pediatric patients aged 6 to 16 years, dosing is based on body weight, typically starting at 0.7 mg/kg once daily up to a maximum of 1.4 mg/kg daily.

The maximal effect of a dose adjustment may take 3 to 6 weeks to be fully realized, which guides the timing for any subsequent dose modifications. In the event of a missed dose, the standard approach is to not take a double dose; the standard regimen should be resumed at the next scheduled time.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Medzar

Medzar (Losartan Potassium) was observed in studies exploring several cardiovascular and kidney-related conditions. The research base for the medicine is primarily derived from Randomized Controlled Trials (RCTs), where the medicine is compared against a placebo or other active treatments, and subsequent meta-analyses that consolidate the data. The research helps contextualize how patients reported their experience and how outcomes evolved in the observed populations.


Evidence for Use in Managing High Blood Pressure (Essential Hypertension)

Research examined Losartan in trials for high circulatory pressure. The studies monitored measured changes in blood pressure (BP) and observed BP patterns over a day, as well as the effect on long-term cardiovascular events. Research explored the medicine's use in pediatric groups, which typically included children aged six years and above.

Short-term and intermediate-term studies reported measurements showing patterns related to BP changes during the observation periods. Data for long-term outcomes are not fully established in children. Reviews noted that research describes group patterns, not personal outcomes, and that follow-up durations were limited for certain groups.


Evidence for Use in Reducing Stroke Risk with Heart Muscle Thickening (LVH)

Large-scale, long-term trials observed over several years focused on high-risk patients who had high blood pressure and an accompanying thickening of the heart muscle, known as Left Ventricular Hypertrophy (LVH). Researchers monitored the occurrence of major cardiovascular events, with a specific emphasis on the incidence of fatal or non-fatal stroke.

Studies described patterns related to the composite cardiovascular endpoint when the medicine was compared against a specific comparator agent. The data also reported patterns related to the incidence of stroke in this specific population.


Gaps in Research and Areas of Uncertainty

The research provides context but also highlights areas where data are still emerging or where the certainty remains low. The main limitations observed in the research include the fact that the results apply only to the populations studied. For instance, the generalizability of stroke research findings is limited to hypertensive patients with LVH, and the finding did not apply to all subgroups within that trial. Comparative evidence showing differences from all other first-line treatments for conditions like heart failure is lacking.

Key Studies & References

  1. Losartan - StatPearls (General evidence review for hypertension and diabetic nephropathy)

Frequently Asked Questions (FAQ)

Common questions about Medzar (FAQ)


Q: How long does it typically take to feel any effect from Medzar?

According to official product information, the maximum reduction in blood pressure from a dose adjustment may take approximately three to six weeks to be fully established. While the medicine starts working after the first dose, the full benefit is reflected by measured changes in blood pressure over time.


Q: What happens if I miss a dose of Medzar?

Regulatory instructions advise that if a dose is missed, not to take a double dose to make up for the missed one. The standard regimen is advised to be resumed at the next scheduled time.


Q: Can Medzar be crushed or split if it's a tablet?

The official guidelines state that Medzar tablets are to be swallowed whole with water. This indicates that the tablets are to be swallowed whole according to the official instructions.


Q: Are the side effects of Medzar permanent?

Official information does not classify common adverse reactions as permanent. Most side effects are observed to be reversible upon stopping the medicine.


Q: Does Medzar cause weight changes?

Official reports on common and uncommon adverse reactions do not list weight gain or loss as a typical side effect of Medzar. However, some swelling (edema) has been noted as a less common occurrence.


Q: What if I take too much Medzar by accident?

If too much Medzar is taken, symptoms officially reported are likely to include significantly low blood pressure (hypotension) and changes in heart rate. Due to the potential for symptomatic low blood pressure, immediate medical evaluation is necessary.


Q: How long does Medzar stay in your system after stopping it?

Official pharmacokinetic data indicates that the active ingredient, Losartan, has a terminal half-life of about 2 hours, and its active form has a half-life of approximately 6 to 9 hours. The half-life refers to the time it takes for half of the substance to be eliminated from the plasma.


Q: Can older adults or seniors use Medzar?

Regulatory documents state that the substance concentration in the blood is similar in elderly and young hypertensive patients. Use is generally not restricted solely due to age, but specific patient health profiles may be reviewed by a healthcare professional.


Q: Are there generic versions of Medzar available?

Yes, Medzar contains the active substance Losartan Potassium, which is available in generic forms approved by regulatory bodies. This means that other companies can manufacture the medicine after patent expiration.


Q: Is Medzar the same type of medicine as [similar common drug name]?

Medzar is definitively classified as an Angiotensin II Receptor Blocker (ARB). Official documentation defines its role as blocking the AT1 receptor, which is a key distinction from other types of blood pressure medications that use different mechanisms of action.


Q: Why do people take Medzar if there are other options?

Regulatory approvals define Medzar's role in lowering high blood pressure and reducing the risk of stroke in certain high-risk patients. The official documentation notes that some benefits have been seen in controlled trials of this specific class of drugs.


Q: Will Medzar interact with my vitamins or herbal supplements?

Official regulatory documents specifically address known interactions with medications, including Potassium-Affecting Agents (such as certain supplements). However, interaction data for most other specific vitamins or herbs are not comprehensively addressed in the official label.


Q: Does Medzar affect my ability to drive or operate machinery?

Official documents state that Medzar may cause side effects like dizziness or lightheadedness in some users. Official caution is noted for activities requiring alertness until a person knows how the medicine affects them.


Q: What should I do if I think I'm having an allergic reaction to Medzar?

The official product label highlights the risk of serious hypersensitivity reactions, such as angioedema (swelling of the face, lips, or throat). Immediate medical evaluation is specified as necessary for these symptoms.


Q: Does Medzar affect sleep?

Official documentation from regulatory bodies lists sleep disorders and insomnia as uncommon adverse reactions that have been reported in clinical studies. Additionally, somnolence (drowsiness) has been reported as a less common reaction.


Q: Is Medzar habit-forming or addictive?

Medzar (Losartan Potassium) is not classified as a controlled substance by regulatory bodies such as the U.S. Drug Enforcement Administration (DEA). This indicates that the medicine is not generally regarded as having a potential for abuse or addiction.


Q: Can I stop taking Medzar suddenly if I feel better?

Regulatory information indicates there is no apparent rebound effect after abrupt withdrawal of the medicine. However, discontinuation of the medicine, or any change to the regimen, is to be decided by a healthcare provider.


Q: Are there any long-term effects of taking Medzar?

The clinical research for Medzar includes large-scale, long-term trials lasting several years. These studies focused on cardiovascular endpoints, and the results describe long-term patterns within the specific patient groups examined.


Q: Is it true that Medzar helps with more than just the main condition?

Regulatory documents strictly define Medzar's approved uses as managing high blood pressure and reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy (LVH). A medicine is only recognized for the specific indications that have been officially studied and approved.


Q: Can Medzar be used to prevent a condition?

The official indication includes its use to reduce the risk of stroke in a specific high-risk patient population. For its main purpose, the medicine is intended for the management and treatment of established high blood pressure, rather than general prevention.


Q: Can people with a history of certain mental health conditions take Medzar?

Official reports on adverse reactions list psychiatric effects like anxiety, sleep disorder, depression, and nervousness as having been reported. The official regulatory label does not typically list specific mental health diagnoses as contraindications.


Q: What kind of monitoring is typically done when a person starts Medzar?

Due to the potential for hyperkalemia (high potassium levels) and effects on kidney function, official guidelines recommend periodic monitoring of a patient's serum potassium levels and kidney function (e.g., creatinine clearance) in susceptible individuals.


Q: What are the signs that Medzar is working?

Medzar is intended to provide a sustained reduction in high blood pressure, which is a clinical measurement. The drug's effectiveness is primarily determined by measured reductions in blood pressure readings taken by a healthcare professional.


Q: Is Medzar a new drug, or has it been around for a while?

The active ingredient in Medzar, Losartan Potassium, received its Initial U.S. Approval in 1995, indicating that this substance has been utilized in medical practice for several decades.


Q: Why is Medzar only approved for certain uses?

A medicine is approved by regulatory bodies, such as the FDA, only for the specific uses and patient populations that were rigorously studied in clinical trials and for which the safety and effectiveness profile was demonstrated.

How should Medzar be stored and disposed of?

How to Store and Dispose of Medzar?

Medzar tablets must be stored at controlled room temperature, generally between 15 C and 30 C (59 F and 86 F), with the temperature not exceeding 30 C. To maintain stability, the medication must be protected from light and moisture, and tablets must not be frozen or stored in damp areas. The container must be kept tightly closed.

If prepared as an oral suspension, the product requires refrigeration (2 C to 8 C) and must be discarded after 28 days. Keep all medicines out of the sight and reach of children.

Disposal must be conducted in accordance with local regulations for unused or expired medicines. Do not dispose of Medzar via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Medzar found in:

A-Z Index: